Developer docs
API playgroundTry for free, no card

Search company profiles

European League Against Rheumatism

Full company profile

uuid002h9wt

Namestring
European League Against Rheumatism
Websiteurl
eular.org
Company typeenum
Private
Founded yearint
1947
Descriptiontext

The European League Against Rheumatism (EULAR) is a non-profit organization founded in 1947, registered in Kilchberg, Germany, and operating with 51–100 employees. Per its public positioning, it functions as a central platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology, implying a federation-style model that coordinates European scientific activity in the field. The organization serves the rheumatology research and clinical community — physicians, researchers, allied health professionals, and constituent national societies — through programs that, based on the platform framing, likely include research funding calls, scientific congresses, peer-reviewed publishing, and clinical guideline development, although the input data does not enumerate these product lines.

No proprietary technology stack, product catalog, or pricing model is disclosed in the available data; the company_type field is non_profit and the firmographic data set contains empty arrays for revenue model, products and services, and pricing details. As a private non-profit federation, EULAR's revenue mechanics are not directly observable from the input, and the source content was a loading/verification page that did not surface commercial terms, partnership details, or product descriptions. The most analytically significant gap is the absence of any revenue, headcount trend, member count, or strategic action data, which limits the depth of any investment-grade assessment.

Short descriptiontext

European League Against Rheumatism (EULAR) is a non-profit federation founded in 1947 and headquartered in Kilchberg, Germany, that serves as a pan-European platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology for clinicians, researchers, and national societies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKilchberg, Germany
HQ citystring
Kilchberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
rheumatology research, medical education, scientific congress, clinical guidelines, patient advocacy
NAICS code2 codes
  • Professional Organizations81392
  • Business Associations813910
SIC code3 codes
  • Services-Membership Organizations8600
  • Services-Health Services8000
  • Services-Misc Health & Allied Services, Nec8090
Product category
Medical Association Services
Social media profiles2 records
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

European League Against Rheumatism (EULAR) is a non-profit organization that serves as a central platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology. It develops scientific congresses, educational programs, clinical guidelines, and promotes collaboration among researchers, clinicians, and patient organizations across Europe.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1EULAR Annual European Congress of Rheumatology
CategoryScientific Congress
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

International research-focused society dedicated to osteoarthritis, a major condition within rheumatology. Comparable to EULAR as a non-profit organization promoting research and education in a rheumatic disease area, though narrower in scope.

TypeBroad incumbent
Description

European professional society for respiratory medicine. Comparable to EULAR as a peer European medical specialty society structured around research, education, and advocacy, although focused on respiratory rather than rheumatic disease.

TypeDirect peer
Description

Global umbrella organization for rheumatology associations, coordinating activities among regional and national societies worldwide. Directly comparable to EULAR in its convening and federation role, though operating at a global rather than European scope.

TypeDirect peer
Description

U.K.-based professional society for rheumatology professionals, providing education, research support, and clinical guidance. Comparable as a national-level rheumatology association operating under a similar member-based, research-promoting model.

TypeBroad incumbent
Description

Largest European professional association for cardiovascular medicine. Comparable to EULAR as a major European specialty society with similar governance, congress, and research-facilitation models, but operating at materially larger scale in cardiology rather than rheumatology.

TypeDirect peer
Description

European society for pediatric and adolescent rheumatology. Directly comparable as a European specialty society within the broader rheumatology field, with overlapping member constituencies and similar non-profit, research-promoting structure.

TypeDirect peer
Description

The leading U.S. professional association for rheumatology, serving rheumatologists and health professionals through research, education, and advocacy. Closely comparable to EULAR in mission, member services, and annual meeting structure as the corresponding North American counterpart.

TypeDirect peer
Description

German national professional society for rheumatology. Comparable as a national-level rheumatology association with a similar member-driven, research-promoting model, and a frequent partner and overlapping constituency with EULAR's German and European membership.

9Pan American League of Associations for Rheumatology
TypeRegional player
Description

Regional federation of rheumatology societies across the Americas. Structurally similar to EULAR as a regional umbrella, but focused on the Americas rather than Europe, making it a comparable peer for benchmarking rather than a direct competitor.

10Asia Pacific League of Associations for Rheumatology
TypeRegional player
Description

Regional umbrella for rheumatology societies across the Asia-Pacific region. Comparable as a regional federation of rheumatology associations with analogous research-promotion and educational missions, serving a different geographic footprint than EULAR.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

European League Against Rheumatism

Medical Association Serviceseular.org

European League Against Rheumatism (EULAR) is a non-profit federation founded in 1947 and headquartered in Kilchberg, Germany, that serves as a pan-European platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology for clinicians, researchers, and national societies.

What European League Against Rheumatism does

The European League Against Rheumatism (EULAR) is a non-profit organization founded in 1947, registered in Kilchberg, Germany, and operating with 51–100 employees. Per its public positioning, it functions as a central platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology, implying a federation-style model that coordinates European scientific activity in the field. The organization serves the rheumatology research and clinical community — physicians, researchers, allied health professionals, and constituent national societies — through programs that, based on the platform framing, likely include research funding calls, scientific congresses, peer-reviewed publishing, and clinical guideline development, although the input data does not enumerate these product lines.

No proprietary technology stack, product catalog, or pricing model is disclosed in the available data; the company_type field is non_profit and the firmographic data set contains empty arrays for revenue model, products and services, and pricing details. As a private non-profit federation, EULAR's revenue mechanics are not directly observable from the input, and the source content was a loading/verification page that did not surface commercial terms, partnership details, or product descriptions. The most analytically significant gap is the absence of any revenue, headcount trend, member count, or strategic action data, which limits the depth of any investment-grade assessment.

European League Against Rheumatism firmographics

Firmographics
Name
European League Against Rheumatism
Website
https://eular.org
Company type
Private
Founded year
1947
Operating status
Operating
Headcount range
51–100 employees
Short description
European League Against Rheumatism (EULAR) is a non-profit federation founded in 1947 and headquartered in Kilchberg, Germany, that serves as a pan-European platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology for clinicians, researchers, and national societies.
Ownership category
akta.pro rank

Where European League Against Rheumatism is headquartered

Location

Headquarters

HQ city
Kilchberg
HQ country
Germany
HQ region
Europe

Markets served

European League Against Rheumatism business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

European League Against Rheumatism product offering

Product offering

Core offering

European League Against Rheumatism (EULAR) is a non-profit organization that serves as a central platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology. It develops scientific congresses, educational programs, clinical guidelines, and promotes collaboration among researchers, clinicians, and patient organizations across Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • EULAR Annual European Congress of Rheumatology

Companies that use European League Against Rheumatism

Customer profile

Ideal customer profiles1 record

European League Against Rheumatism technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

European League Against Rheumatism partnerships and signals

Strategic signal

Recent moves2 records

European League Against Rheumatism competitors and assessment

Company assessment

Direct peers

  • Osteoarthritis Research Society International: International research-focused society dedicated to osteoarthritis, a major condition within rheumatology. Comparable to EULAR as a non-profit organization promoting research and education in a rheumatic disease area, though narrower in scope.
  • International League of Associations for Rheumatology: Global umbrella organization for rheumatology associations, coordinating activities among regional and national societies worldwide. Directly comparable to EULAR in its convening and federation role, though operating at a global rather than European scope.
  • British Society for Rheumatology: U.K.-based professional society for rheumatology professionals, providing education, research support, and clinical guidance. Comparable as a national-level rheumatology association operating under a similar member-based, research-promoting model.
  • European Society for Paediatric Rheumatology: European society for pediatric and adolescent rheumatology. Directly comparable as a European specialty society within the broader rheumatology field, with overlapping member constituencies and similar non-profit, research-promoting structure.
  • American College of Rheumatology: The leading U.S. professional association for rheumatology, serving rheumatologists and health professionals through research, education, and advocacy. Closely comparable to EULAR in mission, member services, and annual meeting structure as the corresponding North American counterpart.
  • Deutsche Gesellschaft für Rheumatologie: German national professional society for rheumatology. Comparable as a national-level rheumatology association with a similar member-driven, research-promoting model, and a frequent partner and overlapping constituency with EULAR's German and European membership.

Broad incumbents

  • European Respiratory Society: European professional society for respiratory medicine. Comparable to EULAR as a peer European medical specialty society structured around research, education, and advocacy, although focused on respiratory rather than rheumatic disease.
  • European Society of Cardiology: Largest European professional association for cardiovascular medicine. Comparable to EULAR as a major European specialty society with similar governance, congress, and research-facilitation models, but operating at materially larger scale in cardiology rather than rheumatology.

Regional players

  • Pan American League of Associations for Rheumatology: Regional federation of rheumatology societies across the Americas. Structurally similar to EULAR as a regional umbrella, but focused on the Americas rather than Europe, making it a comparable peer for benchmarking rather than a direct competitor.
  • Asia Pacific League of Associations for Rheumatology: Regional umbrella for rheumatology societies across the Asia-Pacific region. Comparable as a regional federation of rheumatology associations with analogous research-promotion and educational missions, serving a different geographic footprint than EULAR.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights4 records

Customer concentration

European League Against Rheumatism social profiles

Digital presence

European League Against Rheumatism financial estimates

Financial estimate

Revenue estimate

Valuation estimate

European League Against Rheumatism leadership team

Management profile

Number of profiles

European League Against Rheumatism funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

European League Against Rheumatism M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European League Against Rheumatism

What does European League Against Rheumatism do?

European League Against Rheumatism (EULAR) is a non-profit organization that serves as a central platform to facilitate and stimulate innovative basic and clinical research projects in rheumatology. It develops scientific congresses, educational programs, clinical guidelines, and promotes collaboration among researchers, clinicians, and patient organizations across Europe.

Is European League Against Rheumatism a public or private company?

European League Against Rheumatism is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was European League Against Rheumatism founded?

European League Against Rheumatism was founded in 1947. It employs 51 to 100 people.

Where is European League Against Rheumatism based?

European League Against Rheumatism is headquartered in Kilchberg, Germany, in the Europe region.

Who are European League Against Rheumatism's main competitors?

Direct peers on record are Osteoarthritis Research Society International, International League of Associations for Rheumatology, British Society for Rheumatology, European Society for Paediatric Rheumatology, American College of Rheumatology and Deutsche Gesellschaft für Rheumatologie. Broad incumbents are European Respiratory Society and European Society of Cardiology. Regional players are Pan American League of Associations for Rheumatology and Asia Pacific League of Associations for Rheumatology.

Does European League Against Rheumatism have an API?

No public API is recorded for European League Against Rheumatism.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTavneos® (avacopan) included in updated EULAR recommendations for the management of AAVVifor Fresenius Medical Care Renal Pharma announced that its drug Tavneos has been included in the updated 2022 EULAR recommendations for managing ANCA-associated vasculitis. The inclusion recognizes Tavneos' ability to induce remission and reduce glucocorticoid toxicity, based on clinical trial data demonstrating superiority over prednisone-based regimens. This endorsement aims to improve patient care by lowering exposure to harmful steroid side effects while maintaining disease control.GlobeNewswireNavidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) CongressNavidea Biopharmaceuticals announced its first interim analysis of the NAV3-31 phase 2b study will be presented as a poster at EULAR Congress 2020. Results showed Tc99m tilmanocept imaging reproducibly distinguished RA joints from healthy controls, with low variability. The company expects the product to enable earlier therapeutic decisions for RA patients.GlobeNewswireCentrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of RheumatologyCentrexion Therapeutics will report data from two clinical studies of CNTX-4975 at the EULAR 2019 Annual Congress in Madrid, including an assessment of cooling methods to reduce procedural pain. The studies involve knee osteoarthritis patients, and the company is refining its cooling procedure for intra-articular injection.GlobeNewswireSamumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual CongressSamumed presented clinical and preclinical data for SM04690 and SM04755 at EULAR 2018 in Amsterdam. Phase 2 data showed SM04690 improved WOMAC pain scores in knee OA, and preclinical data supported its potential as a disease-modifying osteoarthritis drug. The company also highlighted SM04755's potential for tendinopathy and psoriasis.GlobeNewswireCrescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th Annual CongressCrescendo Bioscience announced new Vectra DA data on rheumatoid arthritis treatment response at EULAR in London. The studies showed the test predicts flare after adalimumab discontinuation and guides biologic vs non-biologic therapy choices. Results will be presented as poster presentations.PR NewswireResolve To Present Data On Lupus Studies At International Rheumatology ConferenceResolve Therapeutics announced that it will present data from two clinical studies at the upcoming EULAR Annual European Congress of Rheumatology in London. The presentations include an observational study on immune complexes and results from a phase 1b clinical trial for its lead compound, RSLV-132.